Treatments to boost immune recovery in HIV
Part of Immune system & allergy, Infections clinical trials.
This study tests new treatments to help people with HIV who have low CD4 counts despite antiretroviral therapy. It aims to improve immune function and reduce the risk of infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are aged 18 to 65.
- You have HIV and have been on antiretroviral therapy for over 4 years.
- Your viral load has been undetectable for over 3 years.
- Your CD4 count has stayed below 350 for the past year but above 200.
- You are currently taking a dolutegravir-based ART regimen for at least 1 year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
This trial tests whether adding a traditional Chinese herbal medicine (Qiling Yiqi tablets) to standard HIV treatment can help raise CD4+ T-cell counts in people whose immune systems haven't fully recovered. It may offer a new option for those with persistently low counts despite effective viral suppression.
This study looks at whether certain genetic changes in the HIV virus (called drug resistance mutations) affect how well your immune system recovers after you start HIV treatment. It could help doctors understand why some people on HIV therapy have better immune recovery than others.
This study looks at how certain immune cells (NK cells) behave in people who have been on HIV treatment for a long time. It aims to understand why some people's immune systems respond differently, which could help improve future treatments.
This trial tests a medicine called glatiramer acetate (often used for multiple sclerosis) to see if it can help improve the immune system (CD4 cells) in people with HIV who have low CD4 counts despite successful viral suppression. It involves injecting the medicine under the skin three times a week for the study period.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Hear when a new Immunological Non-Responders in People With HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.